Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.

You may also be interested in...



Multaq REMS May Be Revamped As Label Adds New Risks

After several years of regulatory struggles Sanofi’s anti-arrhythmic Multaq finally got to market. But results from a new study have drawn attention to safety problems in higher-risk patients and could damage the drug’s commercial opportunity.

European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings

Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.

Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter

Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.

Related Content

Topics

UsernamePublicRestriction

Register

PS072813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel